The CTNS-MTORC1 axis couples lysosomal cystine to epithelial cell fate decisions and is a targetable pathway in cystinosis

Autophagy. 2024 Jan;20(1):202-204. doi: 10.1080/15548627.2023.2250165. Epub 2023 Aug 24.

Abstract

Differentiation and fate decisions are critical for the epithelial cells lining the proximal tubule (PT) of the kidney, but the signals involved remain unknown. Defective cystine mobilization from lysosomes through CTNS (cystinosin, lysosomal cystine transporter), which is mutated in cystinosis, triggers the dedifferentiation and dysfunction of the PT cells, causing kidney disease and severe metabolic complications. Using preclinical models and physiologically relevant cellular systems, along with functional assays and a generative artificial intelligence (AI)-powered engine, we found that cystine storage imparted by CTNS deficiency stimulates Ragulator-RRAG GTPase-dependent recruitment of MTORC1 and its constitutive activation. In turn, this diverts the catabolic trajectories and differentiating states of PT cells toward growth and proliferation, disrupting homeostasis and their specialized functions. Therapeutic MTORC1 inhibition by using low doses of rapamycin corrects lysosome function and differentiation downstream of cystine storage and ameliorates PT dysfunction in preclinical models of cystinosis. These discoveries suggest that cystine may act as a lysosomal fasting signal that tailors MTORC1 signaling to direct fate decisions in the kidney PT epithelium, highlighting novel therapeutic paradigms for cystinosis and other lysosome-related disorders.

Keywords: autophagy; chronic kidney disease; cystinosis; drug repurposing; lysosome; nutrient sensing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Transport Systems, Neutral* / metabolism
  • Artificial Intelligence
  • Autophagy
  • Cystine / metabolism
  • Cystinosis* / metabolism
  • Epithelial Cells / metabolism
  • Lysosomes / metabolism
  • Mechanistic Target of Rapamycin Complex 1 / metabolism

Substances

  • Amino Acid Transport Systems, Neutral
  • Cystine
  • Mechanistic Target of Rapamycin Complex 1

Grants and funding

We are grateful to the Cystinosis Research Foundation [Irvine, CA, USA; project grants CRFS-2017-007 (OD and AL), CRFS-2020-005 (OD and AL) and CRFS 2022-003 (OD)], the Swiss National Science Foundation (project grant 310030_189044 to OD and project grant 310030_215715 to AL), the University Research Priority Program of the University of Zurich (URPP) ITINERARE - Innovative Therapies in Rare Diseases (OD and AL) and TrainCKDis funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860977 (OD).